Autoimmune Disease Drugs
Publication Date
March 2024
USD 108.71 billion
USD 180.67 billion
USD 116.79 billion
Autoimmune Disease Drugs Market by Indication (Diabetes Mellitus Type 1, Multiple Sclerosis, Rare Diseases), Drug Class (Anti-Inflammatory, Antihyperglycemic, Immunosuppressants), Distribution - Global Forecast 2024-2030

[180 Pages Report] The Autoimmune Disease Drugs Market size was estimated at USD 108.71 billion in 2023 and expected to reach USD 116.79 billion in 2024, at a CAGR 7.52% to reach USD 180.67 billion by 2030.

Autoimmune Disease Drugs Market
To learn more about this report, request a free sample copy
Autoimmune diseases occur when the immune system mistakenly attacks the body's cells, tissues, and organs, resulting in various disorders such as rheumatoid arthritis, lupus, and Type 1 diabetes. Autoimmune disease drugs include various pharmaceuticals that suppress or modulate the immune system to reduce the severity of autoimmune disorders. These drugs encompass a range of treatment types, including non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, and biologics that specifically target immune responses. The primary drivers include the prevalence of autoimmune diseases globally, increased awareness and understanding of autoimmune disorders, advancements in medical research leading to the development of more effective and targeted drugs, and the increasing investment in healthcare infrastructure and research and development activities by governments and private entities. The high cost of treatment, stringent regulatory policies, and adverse effects associated with some autoimmune disease drugs are significant restraints. Challenges include the need for innovative therapies with fewer side effects, overcoming the complexities in diagnosing autoimmune diseases, and navigating the patent expiry of major drugs leading to the influx of generics and biosimilars, which could affect market dynamics. Emergent opportunities encompass the growing need for personalized medicine approaches, the potential for expansion in emerging economies, and the ongoing development of novel therapeutic drugs and treatment modalities driven by biotechnological advances.
Autoimmune Disease Drugs Market - Global Forecast 2024-2030
To learn more about this report, request a free sample copy
FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Autoimmune Disease Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Autoimmune Disease Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Autoimmune Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AESKU.GROUP GmbH & Co. KG, AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, Biogenuix Medsystems Private Limited, bioMerieux S.A., Exagen, Inc., F. Hoffmann-La Roche AG, Novartis AG, Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and Werfen S.A..

Market Segmentation & Coverage

This research report categorizes the Autoimmune Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Diabetes Mellitus Type 1
    • Multiple Sclerosis
    • Rare Diseases
    • Rheumatic Diseases
  • Drug Class
    • Anti-Inflammatory
    • Antihyperglycemic
    • Immunosuppressants
    • Interferons
    • Nonsteroidal Anti-Inflammatory Drugs
  • Distribution
    • Hospital Pharmacies
    • Online Stores
    • Retail Pharmacies

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Autoimmune Disease Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Autoimmune Disease Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Autoimmune Disease Drugs Market?
  4. What is the market share of the leading vendors in the Autoimmune Disease Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Autoimmune Disease Drugs Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Autoimmune Disease Drugs Market, by Indication
  7. Autoimmune Disease Drugs Market, by Drug Class
  8. Autoimmune Disease Drugs Market, by Distribution
  9. Americas Autoimmune Disease Drugs Market
  10. Asia-Pacific Autoimmune Disease Drugs Market
  11. Europe, Middle East & Africa Autoimmune Disease Drugs Market
  12. Competitive Landscape
  13. Competitive Portfolio
Companies Mentioned
  • Abbott Laboratories
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • Biogenuix Medsystems Private Limited
  • bioMerieux S.A.
  • Exagen, Inc.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • Werfen S.A.
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Autoimmune Disease Drugs Market
The Global Autoimmune Disease Drugs Market size was estimated at USD 108.71 billion in 2023 and expected to reach USD 116.79 billion in 2024.
The Global Autoimmune Disease Drugs Market to grow USD 180.67 billion by 2030, at a CAGR of 7.52%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.